Let me start by clarifying what I mean by “reactive.”

The CICO model treats the body as if it reacts to calorie availability in a direct, predictable, mechanical way. Less energy available means weight must go down. More energy available means weight must go up. Create a deficit, and fat loss must follow. Create a surplus, and fat gain must follow. Put the numbers into the calculator, and the body should obey.

That is the CICO model.

The body does not work that way.

The body is a dynamic, adaptive, living system that regulates its own energy economy. It does not passively receive calories and mechanically convert the difference into fat loss or fat gain. It changes fuel use. It changes expenditure. It changes efficiency. It changes how much energy is recycled, conserved, dissipated, mobilized, or stored.

That does not mean anyone is denying thermodynamics. That accusation is lazy and usually means the person does not understand the argument.

Energy conservation is real. Calories are energy. You cannot create energy from nowhere. You cannot spend energy without energy. Nobody serious is denying that.

But CICO is not thermodynamics. CICO is not a law. CICO is a model. It is disputed greatly upstream in clinical literature.

Thermodynamics says energy is conserved. It does not say a living organism must lose body fat in a clean, linear, predictable way because someone wrote a deficit into an app. It does not say every surplus calorie must be efficiently stored as body fat. It does not say the body has no regulatory systems.

That is the distinction CICO people keep dodging.

One of the cleanest examples is the lactate shuttle.

Most people think of exercise in false, grossly oversimplified terms: “I burned 400 calories, so I burned 400 calories worth of fat.” That is not how exercise metabolism works.

During exercise, lactate is often treated like a waste product. It is not. Lactate is usable fuel. Working muscle can produce lactate, but that lactate can circulate to other tissues, be converted back into pyruvate, and be used for energy. It can also help support glucose production through gluconeogenesis.

In plain English, the body can recycle a byproduct of exercise back into usable energy. It's not perpetual, but it sure as hell can dramatically reduce physical energy expenditure.

That alone breaks the simplistic version of “calories out.”

Exercise increases energy demand. That part is true. But increased demand does not mean the body must pull every missing calorie directly from body fat. The body can draw from glucose, glycogen, fatty acids, lactate, glycerol, ketones, amino acids, and other fuel intermediates. It can recycle lactate while the work is still happening. It can shift fuel sources depending on intensity, oxygen availability, hormonal state, and energy availability.

So “calories burned” is not the same thing as “fat mobilized.”

That is the first failure of the CICO model. It treats energy output like a clean withdrawal from stored fat, when the body is actually running a flexible fuel system.

Now flipside...

If energy is abundant, the body is not required to extract maximum usable energy from every recyclable substrate. It does not have to behave like a desperate survival machine trying to squeeze every last drop out of lactate recycling and fuel conservation. The body can afford to be less efficient.

That is the other side CICO people ignore.

Under lower-energy conditions, the body can recycle substrate and conserve energy more aggressively. Under higher-energy conditions, the body can become more wasteful. It can spend more energy processing food. It can produce more heat. It can increase spontaneous movement. It can route more energy through inefficient cycling. It can reduce the efficiency with which surplus intake becomes stored body fat.

Same body. Same laws of physics. Different biological state.

That is the point.

The body is not trying to satisfy a calorie calculator. It is trying to maintain stability.

This is why the popular CICO model fails. It assumes the body is reactive in a simple direction: deficit equals loss, surplus equals gain. But physiology is regulatory, not merely reactive. The body responds to low energy availability by conserving, recycling, reducing expenditure, increasing hunger, and making continued loss harder. It can respond to high energy availability by increasing waste, heat, movement, substrate cycling, and inefficiency.

Again, none of that violates thermodynamics.

This is thermodynamics running through biology.

And this is not just theoretical biochemistry. The clinical outcomes are obvious.

First, BMR downregulation exists. During caloric restriction and weight loss, energy expenditure can fall beyond what would be expected from tissue loss alone. That is adaptive thermogenesis. A smaller body costs less energy to maintain, yes, but the body also adapts regulatory systems in a way that pushes expenditure lower and hunger higher. That means the deficit written on paper is not necessarily the deficit the body continues to experience in reality.

Second, BMR is not perfectly predictable in the first place. Johnstone et al. directly measured basal metabolic rate and found that even after accounting for fat-free mass, fat mass, age, and other variables including leptin, 26% of BMR variance remained unexplained. Sex was not a significant predictor after adjustment. That is a direct problem for CICO. Those body's have adjusted to match it's energy available beyond what we fully understand as "predictable" or "expected".

Third, weight loss is non-linear. Static calorie rules fail because expenditure changes over time. Early loss slows. Maintenance calories shift. Activity costs change. Resting expenditure changes. A 500-calorie "deficit" does not remain a deficit forever just because an app keeps printing the same number. Purposeful overfeeding studies and general population intake show the same non-linear impacts of caloric increase resisting fat gain much more than expected as well. In other words, a "surplus" doesn't remain a surplus forever either. Meaning, there's ample clinical evidence the body resists weight change in both directions. Both with extensive, mechanistic, physiological explanations to explain the clinical outcomes.

That is just part of the evidence stack in plain terms. They demonstrate that the body has mechanisms that recycle, reroute, conserve, waste, and redistribute energy depending on context. The lactate shuttle is just one of many mechanistic responses that serves as a good example because it can impact both directions.

So when someone says, “CICO is just thermodynamics if you could do the math precisely,” they have no clue about the gamut of underlying physiological mechanisms of energy metabolism. Thermodynamics says energy is conserved. It does not say weight change is predictably determined by intake and expenditure arithmetic in a living organism. Those are not the same claim.

Energy balance is real. Calories matter. But CICO is bunk because it takes a dynamic, adaptive, substrate-recycling, expenditure-adjusting biological system and pretends it is a fixed math equation. The body is not a calorie calculator. It is a living system that regulates energy availability, and that is why CICO fails as a model.

References

Brooks GA. The science and translation of lactate shuttle theory. Cell Metab. 2018;27(4):757-785. doi:10.1016/j.cmet.2018.03.008

Emhoff CW, Messonnier LA, Horning MA, Fattor JA, Carlson TJ, Brooks GA. Direct and indirect lactate oxidation in trained and untrained men. J Appl Physiol (1985). 2013;115(6):829-838. doi:10.1152/japplphysiol.00538.2013.

Johnstone, Alexandra & Murison, Sandra & Duncan, Jackie & Watson, Kellie & Speakman, John. (2005). Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. The American journal of clinical nutrition. 82. 941-8. 10.1093/ajcn/82.5.941.

Rosenbaum M, Leibel RL. 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol. 2014;223(1):T83-T96. doi:10.1530/JOE-14-0358.

Overfeeding studies: https://archive.unu.edu/unupress/food2/UID08E/UID08E05.HTM

Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, Swinburn BA. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826-837. doi:10.1016/S0140-6736(11)60812-X.

I just wanted to first say I value you being here. You have been lead astray. You have been given falsehoods. You have had profit over people dominating the narrative.

So here it goes.

This is the secret you must know. You need to know. The secret they've all been hiding from you.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam at nisi nunc. Quisque nisi est, mollis nec arcu id, dictum fringilla lorem. Nulla nec iaculis tellus. Nam ut nulla eget purus feugiat accumsan vel eu urna. Mauris pretium metus odio, in gravida mauris ullamcorper quis. Donec gravida euismod tellus vitae blandit.

There are no secrets. The physiology is known. Anything claiming to be a secret is bullshit.

If its not in clinical science and known physiology, its bunk. If its in clinical literature, it's not a secret.

Stop looking for magic tricks. Stop watching videos. Stop listening to influencers.

Start reading clinical studies.

Myth-busting is arguably the biggest NP-hard problems in public health communication.

And yes, NP-hard means NP-hard, so calling one version “bigger” is a little like talking about degrees of infinity. Technically possible, but usually not the point of the conversation. With health and nutrition myths, though, it almost feels appropriate, because the difficulty does not scale normally.

The problem is not just that people believe one false claim. The problem is that there are usually dozens of myths attached to every basic physiological or clinical fact.

For example, one of the most boring but important truths in nutrition is that no diet is inherently superior for everyone. Different diets can work through overlapping mechanisms: energy intake, adherence, food quality, protein intake, satiety, glycemic control, reduced ultra-processed food intake, and improved structure. That should not be controversial.

But try telling that to a keto or carnivore community. You will get flooded with claims about carbs, insulin, seed oils, ancestral eating, plant toxins, metabolic superiority, or how every other diet is “just starvation.”

Then tell a vegan or vegetarian community that keto and carnivore are not uniquely superior, and they may agree immediately. But then tell them plant-based diets are also not inherently superior for every person, and suddenly the same tribal reflex appears in a different costume.

That is diet tribalism. It is not just disagreement. It is identity protection.

People do not merely hold diet beliefs. They often identify with them. The diet becomes a moral framework, a social group, a personal success story, a redemption arc, a political signal, or proof that they were smarter than everyone else. Once that happens, correcting the belief feels like attacking the person.

That is why nutrition myths are so durable. They are not just information errors. They are identity beliefs protected by anecdotes, community reinforcement, selective evidence, and emotional investment.

This is also why the truth often sounds less believable than the myth.

The truth is usually conditional. It depends on context, population, adherence, physiology, baseline health, intervention design, and outcome measured. The myth is simple. The myth is emotionally satisfying. The myth gives people a villain. Carbs. Fat. Meat. Plants. Seed oils. Calories. Doctors. Big Food. Big Pharma. Influencers. Pick your mascot.

The truth says, “It depends.”

The myth says, “Everyone else is wrong.”

Guess which one spreads faster.

There is another layer that makes this worse: many “myth-busting” articles are myths themselves. A lot of health websites, institutional pages, influencer posts, and professional organization blurbs present themselves as correcting misinformation while quietly pushing their own oversimplifications.

Those pages are not automatically clinical evidence. They are not magically peer-reviewed because a large organization published them. They can be outdated, shallow, politically safe, poorly sourced, or flatly contradicted by clinical literature. A “myth” article can absolutely be myth propagation with better branding.

Some myths are directly debunked by clinical studies and still survive anyway.

Very low energy diets and prolonged fasting are good examples. The lazy mainstream framing is often that they are inherently dangerous, reckless, or disordered. But clinically structured severe energy restriction and fasting protocols have been studied as therapeutic tools. They are not appropriate for everyone, and they require context, but the blanket claim that they are inherently reckless is not a scientific position. It is a stigma position.

And yet, how much of that nuance made it into mainstream nutrition discourse? Almost none of it.

That is the actual problem. Myth-busting does not mean correcting one sentence. It means untangling a whole ecosystem of bad assumptions, identity beliefs, stigma, tribal loyalty, outdated institutional messaging, and selective interpretation of evidence.

This is why my books and material have mostly avoided direct myth-busting as the primary structure. It already takes hundreds of pages just to establish the physiology, the clinical evidence, and the practical solution path. If you stop every three paragraphs to debunk every false claim someone might bring up, the material collapses under the weight of digressions.

Debunking myths can be useful. It can clarify physiology. It can expose bad reasoning. It can show why a popular belief is false.

But myth-busting is not the same thing as building understanding.

That distinction matters.

If all you do is chase myths, the myth-makers still control the conversation. They decide the frame, the vocabulary, the villain, the emotional hook, and the next ridiculous claim that everyone has to waste time answering. You end up playing defense forever against people who are not even trying to understand the subject honestly.

At some point, the better move is to stop letting bad claims set the agenda.

You establish what is true. You explain the physiology. You show the clinical evidence. You identify the mechanisms that matter. You separate therapeutic tools from stigma. You separate diet methods from diet identities. You separate outcomes from ideology.

Then, when the myths come up, they are not the center of the discussion anymore. They are just debris on the side of the road.

That is where I am trying to go next with this material. Not just “here is why this claim is wrong,” but “here is the structure that makes the claim collapse in the first place.”

Because the real goal is not to win every argument against every myth.

The ultimate goal is to make the myths unnecessary.

Stored fat is only useful if the body can release it. In a normal fasting state, insulin falls, lipolysis rises, stored triglycerides are broken down, glycerol is sent to the liver, and free fatty acids are released into circulation to be oxidized for energy. Insulin resistance disrupts that shift. When insulin remains inappropriately elevated, fat breakdown stays more suppressed than it should, storage remains favored over release, and adipose tissue holds on to energy that should be entering circulation. This is the opening metabolic problem. Insulin resistance is not just a glucose problem. It is a fuel-access problem. A person may be eating less, but if stored energy remains harder to mobilize, the deficit becomes much harder to cover cleanly from internal fuel.

That is why a calorie deficit on paper does not always translate cleanly into fat loss in practice. The deficit only works smoothly when stored energy can be mobilized to cover the gap left by reduced intake. If fat mobilization is blunted, intake falls while fuel release remains restricted. Stored energy is present, but access to it is impaired. Elevated insulin keeps triglycerides from being broken down effectively, so adipose tissue holds on to energy that should be released during fasting or between meals. This is one of the main reasons insulin resistance can make fat loss feel disproportionately difficult. The problem is not simply that excess energy is present. It is that the body is worse at getting to it when conditions require it.

That impaired fuel access also affects the transition into ketosis. Ketosis depends on prior fat mobilization. Free fatty acids have to be released first, delivered to the liver, and increasingly used as glucose availability falls. If that upstream release is impaired, the downstream shift is delayed with it. Insulin resistance therefore does not just slow fat loss in a vague sense. It slows the handoff from greater glucose dependence to greater reliance on fat-derived fuel. Ketosis is not triggered by effort or by the mere absence of food. It is the downstream result of a successful shift in fuel handling. Insulin has to fall, adipose tissue has to release fatty acids, and the liver has to convert enough of that incoming fat into ketone bodies to begin covering the energy gap. When insulin resistance interferes with that sequence, the problem is not a lack of stored energy. The problem is delayed access to it.

That delay has practical consequences. In a more insulin-sensitive state, the shift away from incoming glucose and toward stored fat is cleaner. In an insulin-resistant state, the body remains more dependent on glucose for longer while being less prepared to replace that glucose with fat-derived fuel. This is poor metabolic flexibility in practice. The person is not just carrying excess stored energy. The person is worse at switching to it. That is one reason moderate restriction so often produces less meaningful change than people expect. If insulin resistance is already suppressing fat mobilization hard enough to delay the transition into ketosis, then modest deficits often do not create enough physiological pressure to break that pattern decisively. Weight may still go down, but often more slowly, less substantially, and with far less metabolic improvement than people expect.

This is where aggressive restriction becomes more consequential. Insulin resistance can delay entry into meaningful ketosis and make the early phase of severe caloric restriction or prolonged fasting substantially harder. The system is being pushed away from incoming food, but it is not yet efficient at running on stored fat and ketones instead. Glucose reliance remains elevated while ketone availability lags behind. That mismatch is not a minor inconvenience. It is a transitional fuel deficit. The body is being asked to function with less incoming energy before it has gained reliable access to internal replacement fuel. That is the real significance of delayed ketosis in insulin resistance. It is not just that ketones appear later on a meter. It is that the body remains trapped longer in an unstable middle state, no longer being fed normally but not yet fully able to support itself from stored fat.

That is also where the safety issue begins. When insulin resistance is present, aggressive regimens are not just harder. They are less stable. Blood glucose is already poorly controlled in the fed state, which is why insulin-resistant people tend to spike higher and faster after carbohydrate intake. But the problem does not disappear when food is removed. It changes form. Once intake drops sharply, glucose can also become less stable on the way down, especially before fat mobilization and ketone production are strong enough to cover the gap. The immediate danger is in that transition. The person remains more glucose-dependent while losing reliable access to both dietary glucose and internal replacement fuel. This is why early symptoms tend to appear sooner and hit harder in insulin-resistant people.

Fatigue, dizziness, shakiness, irritability, brain fog, headaches, and migraines are not random discomforts in that setting. They are signs that the fuel transition is not going well. As the mismatch worsens, sweating, nausea, visual disturbance, confusion, and severe weakness can follow. At the far end, the danger is impaired judgment, loss of coordination, fainting, seizures, or loss of consciousness. Glucose can fall low enough that severe symptoms develop before fat mobilization and ketone availability are sufficient to compensate. This is where people make a serious mistake. They treat escalating symptoms as if they are only electrolyte problems and tell others to push through them. That is dangerous. Electrolytes do not fix impaired fuel access, delayed ketosis, or a worsening hypoglycemic state. Once symptoms begin escalating, this is no longer about discomfort tolerance. It is a developing safety problem that can become life-threatening.

This is why very-low-energy diets matter so much in this context. They can drive substantial weight loss and substantial metabolic improvement in a more controlled way than full prolonged fasting. That does not make them easy. It makes them more appropriate as an initial strategy when insulin resistance is significant. Before the body can tolerate a harder transition safely, it often first needs enough metabolic improvement to stop fighting that transition so hard. That is also why these interventions matter beyond simple calorie reduction. They do not just reduce body fat. They can help break the metabolic pattern that was interfering with fat mobilization in the first place. They address excess fat mass and insulin resistance together instead of forcing people to wait through months of weaker change that may not be strong enough to meaningfully move either one.

None of this means insulin resistance makes progress impossible. It means the problem has to be understood correctly. Once it is understood as a fuel-access problem, a delayed-ketosis problem, and a safety problem during aggressive transitions, the logic of intervention becomes much clearer. The goal is not to avoid strong interventions. It is to use them intelligently. That is the positive side of this entire discussion. Insulin resistance is a serious obstacle, but it is not a mystery and it is not untouchable. It can be identified, it can be addressed, and it can improve substantially when the intervention is strong enough and used seriously. The better this is understood, the less likely people are to waste time on weak approaches, ignore warning signs, or treat dangerous symptoms as something to push through. Knowledge here is not just useful. It is protective.

If you are struggling to lose weight, one of the most important things you can do is stop guessing and find out whether insulin resistance is part of the problem. This is one of the most critical “small things” in the chapter because failing to check for it can distort everything that comes after. If insulin resistance is present, it can make hunger worse, energy less stable, ketosis harder to reach, fat mobilization less efficient, and weight loss slower and more frustrating than it should be. That does not make fat loss impossible. It means the body is working under a condition that makes effective fat access harder than it should be.

A lot of people still think weight loss is just a matter of reducing calories and waiting long enough. That is incomplete. Lower intake only helps if the body can actually access stored energy well enough to compensate. When fat mobilization is working properly, reduced intake encourages the body to release and burn stored fat. When fat mobilization is impaired, the experience changes. The person cuts calories, but the body does not shift cleanly into using its own stored fuel. Hunger tends to stay higher. Fatigue becomes more common. Energy becomes less stable. The process feels harder because it is harder. This is one of the reasons insulin resistance matters so much. It does not just affect blood sugar. It affects whether the body can efficiently let go of stored fat in the first place.

Under normal conditions, insulin falls between meals and during fasting, which allows stored fat to be released and used for energy. But in insulin resistance, insulin tends to remain elevated more than it should. That continued signal suppresses lipolysis, slows fat mobilization, and keeps the body biased toward storage when it should be shifting harder toward fuel use. In practical terms, this means the person may lose weight more slowly than expected, may struggle to generate much ketosis, and may continue feeling metabolically trapped even while trying to diet. This is one of the main reasons some people do not just need better discipline. They need one of the biggest metabolic obstacles identified and addressed directly.

This is why testing matters. While there are other tests that can provide broader metabolic or cardiovascular context, insulin resistance is too important to leave unchecked. If it is there, and you are still guessing instead of verifying, then one of the most important factors affecting fat loss, energy stability, and metabolic progress is still being left to assumption. This is not a minor detail. It is one of the biggest physiological obstacles in the entire process, and removing the guesswork around it can eliminate a huge amount of wasted time, frustration, and confusion.

Testing insulin resistance is simple. You can easily test fasting glucose and A1c with your healthcare provider or even schedule labs yourself. You can also do a glucose tolerance test (GTT). While a glucose tolerance test is often mostly associated with gestational diabetes screening, it is especially useful here because it can reflect more recent change than A1c and give a clearer sense of whether meaningful improvement is actually happening. That is the point. This is not some advanced medical hurdle. It is basic verification, and it is far easier than spending months stalled, frustrated, and confused while one of the most important parts of the problem remains unexamined.

For those who want to approximate a GTT at home without consuming straight corn syrup, it is possible to create a simplified version. This process begins with an overnight fast of 8 to 12 hours, during which only water should be consumed. After the fast, measure your fasting blood glucose using a reliable glucometer. Next, consume a known quantity of easily digestible carbohydrates, ideally low in fat and fiber to mimic the rapid absorption of pure glucose. Options include two to three slices of white bread, about one and a half cups of cooked white rice, or a homemade solution using glucose tablets or dextrose powder mixed in water. The latter two options most closely resemble the clinical test while avoiding corn syrup.

After consuming the carbohydrate source, measure your blood glucose at 30 minutes, one hour, and two hours. Under normal circumstances, blood glucose should peak by 30 to 60 minutes and return close to baseline by the two-hour mark. If levels remain elevated–above roughly 140 mg/dL at the two-hour measurement–it may suggest impaired glucose tolerance, but this should always be confirmed with a clinical test. It’s also essential to avoid including high-fat or high-protein foods with the carbohydrate source, as they slow glucose absorption and can skew the results. While this home method can give useful insight, it is not a substitute for formal medical testing, and any concerning results should be discussed with a healthcare provider.

If insulin resistance is there, then that should shape strategy. The priority is not simply to eat less and wait. The priority is to improve the metabolic condition that is interfering with fat access, energy stability, and appetite regulation. Weight loss still matters, but the order of operations matters too. Addressing insulin resistance first is not a distraction from fat loss. In many cases it is what makes better fat loss possible in the first place. This is where a lot of people get the process backwards. They keep trying to force fat loss while ignoring one of the biggest metabolic conditions affecting whether fat loss will work properly in the first place. Then they wonder why the process feels harder than it should.

This is one reason very low-energy diets (VLEDs) deserve far more respect than they usually get. VLEDs are not fringe. They are one of the most studied aggressive dietary interventions in the clinical literature. They have strong evidence for safety, strong evidence for weight loss, and strong evidence for rapid metabolic improvement. They are not magic, and they are not exempt from the need for nutritional adequacy and good implementation. But the basic idea is simple: a VLED is strong enough to attack both problems at once. It reduces energy intake enough to drive substantial fat loss, and it reduces insulin burden enough to improve insulin sensitivity far more quickly than weaker approaches tend to. That is the point. It is not just a weight-loss strategy. It is a metabolic intervention.

That speed matters. In some people with lesser degrees of dysfunction, meaningful reversal can begin appearing in as little as 4 weeks. But the stronger remission and reversal literature more often clusters around 12–16 weeks. That is the real point. VLEDs are capable of producing a fast, decisive physiological shift rather than a slow drift in the right direction. They lower insulin aggressively enough to improve insulin sensitivity, accelerate the move toward fat use and ketosis, and break harder from the metabolic conditions that helped sustain the problem in the first place.

This is where traditional and keto-style approaches need to be judged honestly. Some people do improve with them, but the stronger remission signal there tends to cluster around 6 months, not in the much shorter time frame seen with VLEDs. That matters because it makes VLEDs objectively superior when the goal is to produce a faster and more decisive metabolic shift. Lower-intensity methods may still help some people, but they are generally slower, less forceful, and less likely to change direction quickly when substantial insulin resistance is present.

While it cannot be said that traditional methods never lead to remission after 6 months, if meaningful change has not occurred during the intervention period, the likelihood of it appearing later without stronger intervention is very low. Expecting otherwise would be like expecting additional weight loss after ending the treatment that was supposed to produce it.

That does not mean everyone must use a VLED. It means people should stop pretending all dietary strategies are equal when they are not. If someone is substantially insulin resistant, and especially if fat loss has been unusually hard, energy has been unstable, ketosis has been weak, or glycemic markers remain poor, then using a harder intervention first may make far more sense than spending months hoping a softer one will eventually produce the same result. Sometimes the “small thing” is not minor at all. Sometimes it is identifying the central obstacle and treating it seriously enough to stop wasting time.

If insulin resistance is present, it can sabotage the rest of the plan while the person blames themselves, blames the diet, or keeps searching for a more clever explanation. But this is not some deep, unsolvable mystery.

If you keep crashing because you refuse to look behind you before backing up your vehicle, the issue is not bad luck. It is not bad genetics or an “act of God” either. You’re ignoring the biggest risk in the entire process that can be identified with basic steps. It also likely means you’re ignoring other important factors and much of the continued frustration is self-inflicted. You are choosing guesswork over verification, delay over clarity, and continued struggle over a problem that may be far simpler to identify than you are willing to admit.

Take the simple steps. Get tested. No excuses. If you keep failing while refusing to verify one of the most important variables in the process, that is on you.

TL;DR; Before I'm potentially banned for these clinical truths, no disparagement, we make our choices... The mods just invited me. So I hope this is a sub where clinical literature is respected and welcome.

GLP-1 and dual-incretin therapies are the current stars of tGLP-1 and Dual-Incretin Therapieshe medical weight-loss world for a simple reason: on average, they work better than the other drugs. Liraglutide, semaglutide, and tirzepatide produced the largest average medication-based weight-loss effects in the clinical literature, with tirzepatide and semaglutide clearly sitting at the top end of the range. That is the part everyone hears. What they hear less often is the rest of the deal. These drugs also carry the heaviest gastrointestinal burden, meaningful discontinuation rates, gallbladder risk signals, and a very clear pattern of regain when treatment stops. So yes, they are effective. No, they are not magic. And no, the story is not “take a shot and the problem is solved.”

The first thing to understand is what these drugs are actually doing. They are not fixing your food environment. They are not teaching you how to eat. They are not correcting poor diet structure, poor nutritional quality, or the broader habits that may have helped drive obesity in the first place. They are helping suppress appetite, alter intake, and make adherence easier for many people. That can be a huge advantage. It can also fool people into thinking the drug itself is the solution, when in many cases it is better understood as a powerful compliance aid and chronic-disease management tool. If the quality of the diet is still poor, if protein and micronutrient intake are still weak, if you are still building your life around low-satiety food, or if the rest of your health is being neglected, then the intervention may be shrinking one visible symptom while deeper problems remain. That distinction matters.

Liraglutide was the earlier entrant of the group and, based on the clinical literature, it is the weaker option on average for weight loss. In the cited 56-week study context, mean weight change was about -7.4% versus -3.0% for placebo, with 62.3% reaching at least 5% loss versus 34.4% on placebo. Longer-term data in the 160-week prediabetes cohort still showed a treatment effect, but it was smaller than what later semaglutide and tirzepatide results would make popular. It also came with heavy gastrointestinal tolerability problems, around 10% discontinuation in 56-week trials versus 4% for placebo, and 13% versus 6% discontinuation in the longer trial. Pancreatitis and gallbladder events were not theoretical background noise either; the clinical literature specifically identifies pancreatitis adjudication and higher gallbladder event rates, including cholelithiasis and cholecystitis. That makes liraglutide clinically relevant, but not lightweight.

Semaglutide is where the conversation usually gets more serious. In the clinical literature, semaglutide 2.4 mg produced about -14.9% mean weight loss versus -2.4% for placebo at week 68, with 83.5% achieving at least 5% loss and 66.1% achieving at least 10% loss in that trial context. Those are strong numbers, and they are a major reason the drug changed the public conversation around obesity treatment. But the less glamorous numbers matter too. In pooled adult trials used in the label, nausea was reported at 44% versus 16% for placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, and abdominal pain 20% versus 10%. Discontinuation due to adverse reactions was 6.8% versus 3.2% in the labeled adult studies, and in SELECT, discontinuation due to adverse events rose to 16.6% versus 8.2% in a higher-risk cardiovascular population. The clinical literature also flags acute pancreatitis, gallbladder disease, acute kidney injury through dehydration, heart-rate increase, and monitoring for suicidal ideation. In other words, semaglutide looks strong because it is strong, but it is not clean, effortless, or free.

Tirzepatide, the dual GIP/GLP-1 agonist, pushed the efficacy ceiling even higher in the clinical literature. Depending on dose, mean weight loss at 72 weeks ran from about -15.0% to -20.9% versus -3.1% for placebo, with at least 10% weight-loss response rates ranging from 68.5% to 83.5%. That is why so much of the sales energy has shifted toward it. But the pattern is still the same. The drug buys stronger average results by way of strong biological effect, and that effect comes with strong GI burden. Nausea ran about 25% to 29% versus 8% for placebo, diarrhea 19% to 23% versus 8%, vomiting 8% to 13% versus 2%, and constipation 11% to 17% versus 5%. Permanent discontinuation due to adverse reactions reached 4.8% to 6.7% depending on dose, versus 3.4% for placebo. The clinical literature also identifies serious risks including severe GI disease, acute kidney injury from dehydration, acute gallbladder disease, and psychiatric monitoring, with specific caution around people with prior suicidal behavior or active ideation. That is not a trivial burden. It is a trade.

The most important practical reality across this entire class is not the peak weight-loss number. It is the maintenance problem. The clinical literature is blunt on this point: when treatment is stopped, regain is the rule, not the exception. Semaglutide participants in the STEP-1 extension regained about two-thirds of their prior weight loss within a year after withdrawal, with cardiometabolic measures drifting back toward baseline. In STEP-4, participants switched from semaglutide to placebo gained 6.9% from week 20 to week 68, while those continuing semaglutide lost another 7.9%. Tirzepatide showed the same basic pattern in SURMOUNT-4: after a large open-label lead-in loss of about 20.9%, those who continued the drug kept losing, while those switched to placebo gained 14.0% over the next 52 weeks. Liraglutide looked somewhat less dramatic, but the same principle still held: some regain occurred after stopping, even though a residual difference persisted. That is not a side note. It is the core practical truth of the category. These drugs look best when they are being taken. Stop them, and biology starts pushing back.

That means these therapies should be thought of less like a short-term fat-loss phase and more like chronic disease management. If someone goes on one of these drugs thinking they will use it briefly, lose a dramatic amount of weight, stop, and keep the result with minimal effort, the clinical literature does not support that optimism. Continued therapy maintains benefit. Stopping commonly produces regain, often within months. So the real decision is not just whether to start. It is whether you are willing to accept the monitoring burden, the side-effect burden, the cost burden, the compliance burden, and the possibility that long-term continuation may be what it takes to hold onto a large share of the result. If the answer is no, then the intervention may still have a role, but the decision should be made with less fantasy and more honesty.

There is also a mistake people make when they hear that semaglutide and tirzepatide compare favorably on serious-harm profiles relative to many other obesity interventions. Relative context matters, but it can be badly abused. In the clinical literature’s comparative ranking, semaglutide, tirzepatide, and liraglutide were placed among the safer major interventions when evidence strength and serious-harm profile were weighed together. That does not mean harmless. It means safer relative to things like high-risk surgery, aspiration therapy, or some other drug classes with uglier liabilities. Semaglutide’s SELECT data are important here because they showed reduced major adverse cardiovascular events in obesity without diabetes, while tirzepatide showed low serious adverse event and death rates in the obesity withdrawal trial and noninferiority on cardiovascular outcomes versus dulaglutide in a diabetic high-risk population. Those are meaningful data points. But even then, the class still carries discontinuation, dehydration, gallbladder, pancreatitis, pregnancy, and long-term dependence problems. Relative advantage should not be turned into false reassurance.

Patients also need to understand the monitoring and exclusion side of the equation before they start. The clinical literature repeatedly flags dehydration-related renal injury when GI symptoms become significant, screening for pancreatitis symptoms, monitoring for gallbladder symptoms, mental-health monitoring for suicidal ideation, and pregnancy restrictions because weight loss is not indicated in pregnancy and fetal harm is a concern. In practical terms, that means these are not cosmetic convenience drugs. They come with obligations. If you are taking one while barely eating, vomiting frequently, skimping on protein, neglecting hydration, or assuming the medication excuses bad planning, you are increasing the odds that the drug becomes part of the problem rather than part of the solution.

The honest bottom line is straightforward. GLP-1 and dual-incretin therapies are powerful, and they have earned their place. They can produce major average weight loss. They can improve important disease markers. In semaglutide’s case, the clinical literature also supports a cardiovascular-outcome benefit in a high-risk obesity population. But they are still symptom-management tools with real liabilities. They do not solve poor nutritional status. They do not absolve you from diet structure. They do not guarantee durability off treatment. They do not come without side effects, discontinuation, or risk. For the right patient, they may be entirely appropriate and even one of the better medical options available. For the wrong patient, or for the patient who hears only the sales pitch, they can become another expensive lesson in the difference between weight-loss effect and lasting health improvement.

GLP-1 and dual-incretin therapies are the current stars of the medical weight-loss world for a simple reason: on average, they work better than the other drugs. Liraglutide, semaglutide, and tirzepatide produced the largest average medication-based weight-loss effects in the clinical literature, with tirzepatide and semaglutide clearly sitting at the top end of the range. That is the part everyone hears. What they hear less often is the rest of the deal. These drugs also carry the heaviest gastrointestinal burden, meaningful discontinuation rates, gallbladder risk signals, and a very clear pattern of regain when treatment stops. So yes, they are effective. No, they are not magic. And no, the story is not “take a shot and the problem is solved.”

The first thing to understand is what these drugs are actually doing. They are not fixing your food environment. They are not teaching you how to eat. They are not correcting poor diet structure, poor nutritional quality, or the broader habits that may have helped drive obesity in the first place. They are helping suppress appetite, alter intake, and make adherence easier for many people. That can be a huge advantage. It can also fool people into thinking the drug itself is the solution, when in many cases it is better understood as a powerful compliance aid and chronic-disease management tool. If the quality of the diet is still poor, if protein and micronutrient intake are still weak, if you are still building your life around low-satiety food, or if the rest of your health is being neglected, then the intervention may be shrinking one visible symptom while deeper problems remain. That distinction matters.

Liraglutide was the earlier entrant of the group and, based on the clinical literature, it is the weaker option on average for weight loss. In the cited 56-week study context, mean weight change was about -7.4% versus -3.0% for placebo, with 62.3% reaching at least 5% loss versus 34.4% on placebo. Longer-term data in the 160-week prediabetes cohort still showed a treatment effect, but it was smaller than what later semaglutide and tirzepatide results would make popular. It also came with heavy gastrointestinal tolerability problems, around 10% discontinuation in 56-week trials versus 4% for placebo, and 13% versus 6% discontinuation in the longer trial. Pancreatitis and gallbladder events were not theoretical background noise either; the clinical literature specifically identifies pancreatitis adjudication and higher gallbladder event rates, including cholelithiasis and cholecystitis. That makes liraglutide clinically relevant, but not lightweight.

Semaglutide is where the conversation usually gets more serious. In the clinical literature, semaglutide 2.4 mg produced about -14.9% mean weight loss versus -2.4% for placebo at week 68, with 83.5% achieving at least 5% loss and 66.1% achieving at least 10% loss in that trial context. Those are strong numbers, and they are a major reason the drug changed the public conversation around obesity treatment. But the less glamorous numbers matter too. In pooled adult trials used in the label, nausea was reported at 44% versus 16% for placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, and abdominal pain 20% versus 10%. Discontinuation due to adverse reactions was 6.8% versus 3.2% in the labeled adult studies, and in SELECT, discontinuation due to adverse events rose to 16.6% versus 8.2% in a higher-risk cardiovascular population. The clinical literature also flags acute pancreatitis, gallbladder disease, acute kidney injury through dehydration, heart-rate increase, and monitoring for suicidal ideation. In other words, semaglutide looks strong because it is strong, but it is not clean, effortless, or free.

Tirzepatide, the dual GIP/GLP-1 agonist, pushed the efficacy ceiling even higher in the clinical literature. Depending on dose, mean weight loss at 72 weeks ran from about -15.0% to -20.9% versus -3.1% for placebo, with at least 10% weight-loss response rates ranging from 68.5% to 83.5%. That is why so much of the sales energy has shifted toward it. But the pattern is still the same. The drug buys stronger average results by way of strong biological effect, and that effect comes with strong GI burden. Nausea ran about 25% to 29% versus 8% for placebo, diarrhea 19% to 23% versus 8%, vomiting 8% to 13% versus 2%, and constipation 11% to 17% versus 5%. Permanent discontinuation due to adverse reactions reached 4.8% to 6.7% depending on dose, versus 3.4% for placebo. The clinical literature also identifies serious risks including severe GI disease, acute kidney injury from dehydration, acute gallbladder disease, and psychiatric monitoring, with specific caution around people with prior suicidal behavior or active ideation. That is not a trivial burden. It is a trade.

The most important practical reality across this entire class is not the peak weight-loss number. It is the maintenance problem. The clinical literature is blunt on this point: when treatment is stopped, regain is the rule, not the exception. Semaglutide participants in the STEP-1 extension regained about two-thirds of their prior weight loss within a year after withdrawal, with cardiometabolic measures drifting back toward baseline. In STEP-4, participants switched from semaglutide to placebo gained 6.9% from week 20 to week 68, while those continuing semaglutide lost another 7.9%. Tirzepatide showed the same basic pattern in SURMOUNT-4: after a large open-label lead-in loss of about 20.9%, those who continued the drug kept losing, while those switched to placebo gained 14.0% over the next 52 weeks. Liraglutide looked somewhat less dramatic, but the same principle still held: some regain occurred after stopping, even though a residual difference persisted. That is not a side note. It is the core practical truth of the category. These drugs look best when they are being taken. Stop them, and biology starts pushing back.

That means these therapies should be thought of less like a short-term fat-loss phase and more like chronic disease management. If someone goes on one of these drugs thinking they will use it briefly, lose a dramatic amount of weight, stop, and keep the result with minimal effort, the clinical literature does not support that optimism. Continued therapy maintains benefit. Stopping commonly produces regain, often within months. So the real decision is not just whether to start. It is whether you are willing to accept the monitoring burden, the side-effect burden, the cost burden, the compliance burden, and the possibility that long-term continuation may be what it takes to hold onto a large share of the result. If the answer is no, then the intervention may still have a role, but the decision should be made with less fantasy and more honesty.

There is also a mistake people make when they hear that semaglutide and tirzepatide compare favorably on serious-harm profiles relative to many other obesity interventions. Relative context matters, but it can be badly abused. In the clinical literature’s comparative ranking, semaglutide, tirzepatide, and liraglutide were placed among the safer major interventions when evidence strength and serious-harm profile were weighed together. That does not mean harmless. It means safer relative to things like high-risk surgery, aspiration therapy, or some other drug classes with uglier liabilities. Semaglutide’s SELECT data are important here because they showed reduced major adverse cardiovascular events in obesity without diabetes, while tirzepatide showed low serious adverse event and death rates in the obesity withdrawal trial and noninferiority on cardiovascular outcomes versus dulaglutide in a diabetic high-risk population. Those are meaningful data points. But even then, the class still carries discontinuation, dehydration, gallbladder, pancreatitis, pregnancy, and long-term dependence problems. Relative advantage should not be turned into false reassurance.

Patients also need to understand the monitoring and exclusion side of the equation before they start. The clinical literature repeatedly flags dehydration-related renal injury when GI symptoms become significant, screening for pancreatitis symptoms, monitoring for gallbladder symptoms, mental-health monitoring for suicidal ideation, and pregnancy restrictions because weight loss is not indicated in pregnancy and fetal harm is a concern. In practical terms, that means these are not cosmetic convenience drugs. They come with obligations. If you are taking one while barely eating, vomiting frequently, skimping on protein, neglecting hydration, or assuming the medication excuses bad planning, you are increasing the odds that the drug becomes part of the problem rather than part of the solution.

The honest bottom line is straightforward. GLP-1 and dual-incretin therapies are powerful, and they have earned their place. They can produce major average weight loss. They can improve important disease markers. In semaglutide’s case, the clinical literature also supports a cardiovascular-outcome benefit in a high-risk obesity population. But they are still symptom-management tools with real liabilities. They do not solve poor nutritional status. They do not absolve you from diet structure. They do not guarantee durability off treatment. They do not come without side effects, discontinuation, or risk. For the right patient, they may be entirely appropriate and even one of the better medical options available. For the wrong patient, or for the patient who hears only the sales pitch, they can become another expensive lesson in the difference between weight-loss effect and lasting health improvement.

There's a massive misconception that health changes produces health outcomes: that's patently false as a generality and why moderation fails more than not. The body actually wants to be stable and it naturally resists changes as its default behavior.

Force isnt movement. If your health issue is a heavy block, you can push on it with real actions and improvements, but if the force isn't strong enough to overcome the resistance then it won't move.

Clinical outcomes consistently, repeatedly, and strongly demonstrate this. Moderate "deficits". Intermittent fasting. Moderate excercise. On their own they do almost nothing. Combined they only produce a little.

There's a massive amount of physiology to discuss to explain why, to include epigenetics, and I'm not going to here: that's hundreds of pages to explain and defend adequately. This is where the clinical outcomes matter so much. And those aren't disputable.

This is why "extreme" methods like VLEDs and prolonged fasting aren't exactly extremes: they're often necessary as essential tools for health changes.

If you reject this, here's the tragic irony: it validates your struggle. You're not lazy or broken. Its not "put down the fork". There is real, legitimate resistance even when trying hard.

You've just been handed a broken calculator. And you're being blamed when the numbers don't add up.

That doesn't mean moderate tools have no value. And for those without major health issues they can be a great, sustainable tool. But there are no golden hammers. People need different tools. Moderation doesn't work for everyone.

Overview

Autophagy is one of the most misrepresented topics in the context of fasting. Its complexity and nuance leave ample room for clickbait and so-called “profound realizations.” As a result, a wide range of half-truths are often presented with unwarranted confidence, backed by selective scientific references that are advertised as absolute certainty. Fortunately, autophagy is a topic that can be simplified in a practical manner, and people shouldn’t get caught up in the hype or misled by sensational claims.

Terminology

Autophagy is a vital cellular process through which cells degrade and recycle their own components to maintain homeostasis, especially during stress or nutrient deprivation. The term “autophagy” literally means “self-eating,” and it involves the formation of double-membraned vesicles called autophagosomes that engulf damaged organelles, misfolded proteins, or other cellular debris. These autophagosomes then fuse with lysosomes, where the contents are broken down by enzymes and their building blocks–such as amino acids, lipids, and sugars–are released back into the cytoplasm for reuse. This process not only helps clear damaged or toxic components from cells but also provides essential materials for energy production and biosynthesis during times of need. Autophagy plays crucial roles in development, immune responses, and disease prevention, particularly in conditions like cancer, neurodegeneration, and infections. When properly regulated, autophagy contributes to cellular health and longevity; however, its dysfunction can lead to a range of pathologies.

Discussion

Autophagy increases progressively with caloric and nutrient deprivation, accumulating over time; however, this upregulation has physiological limits, as hormones such as insulin and others that regulate autophagic pathways can only be suppressed to a certain threshold.

It is important to recognize that intermittent fasting (IF) windows do not elicit the same magnitude or duration of autophagic activity as longer, prolonged fasts. Even if autophagy peaks around 16 hours, individuals engaging in extended fasting sustain these elevated levels for significantly longer periods. Therefore, the assertion that IF induces autophagy to the same extent as prolonged fasting is demonstrably incorrect.

That said, autophagic activity begins to taper around day five, indicating that extending fasts beyond this point confers diminishing returns with respect to autophagy. This introduces a nuanced consideration in determining whether periodic prolonged fasting or frequent IF offers greater benefits, as the optimal strategy likely resides in a balance between the two approaches.

Debates regarding autophagy without direct, measurable data are unproductive. If IF provides sufficient autophagy benefits for your health and fits your lifestyle, it is reasonable to continue advocating for it. However, claiming IF is equivalent or superior to prolonged fasting in delivering health benefits related to autophagy is scientifically inaccurate.

Prolonged fasting amplifies and extends the autophagic benefits initiated by IF, but ultimately, the most effective approach is the one that is sustainable over the long term. If IF is more compatible with your lifestyle, it is advisable to adhere to it while acknowledging the current scientific evidence.

Fundamentals

All metabolic processes are influenced by nutrition. Claiming that autophagy is promoted by certain nutritious foods is about as obvious as saying that all cells need energy. Like any metabolic process, autophagy functions best when the body has sufficient stored nutrients to support optimal pathways. However, having the necessary nutrients–or consuming the ones involved in the process–does not trigger autophagy itself!

Autophagy is a continuous process that never fully stops.

In general, autophagy is regulated by factors such as insulin levels and nutrient intake. It doesn’t suddenly start or completely shut off at any point. This means that fasting does not abruptly “activate” autophagy, nor does eating instantly “deactivate” it. However, fasting does accelerate the autophagic response more effectively than other methods, while increased food intake tends to suppress it.

Autophagy is also highly cell-type specific. Different tissues–such as organs, muscle, bone, and neurons–exhibit distinct mechanisms and metabolic triggers for autophagy. While there are overlapping features, these processes are not universally identical across all cell types.

Many autophagy studies are conducted in mice and other laboratory animals. Measuring autophagy often requires invasive methods, and artificially manipulating the process can carry risks. While these animal studies provide valuable insights, directly applying their findings to humans is misleading at best. The complex biological differences between species mean that conclusions drawn from animal research don’t always translate accurately to human health and disease.

That said, this doesn’t mean human research on autophagy is nonexistent. There are numerous studies that use biomarkers and even biopsies in human trials to measure autophagy more directly. However, because of the challenges involved, many studies still combine data from both animal and human experiments when drawing conclusions.

Current studies suggest that autophagy begins to increase significantly between 16 and 24 hours of fasting, with some reports indicating as early as 12 hours. The process appears to peak around 72 hours before tapering off. In other words, autophagy is an S-curve that is minimal until up to around 24 hours of significant caloric deprivation and tapers off after multiple days. However, it’s important to remember that much of this data is derived from, or heavily influenced by, animal studies.

Because autophagy is minimal in a fed state, the initial rise is sometimes marketed as the most significant. However, this increase is only significant from a relative perspective–for example, going from 1% to 20% is a 20-fold increase, but an increase from 20% to 80% is far more meaningful in absolute terms. This is often how the timing of the autophagic response is manipulated to suggest that short-term IF windows are "just as beneficial" as prolonged fasting, but they aren't. That’s not to say you can’t maintain healthy autophagic function without prolonged fasting, but it’s clear that prolonged fasting induces a greater autophagic response than typical IF.

By days four or five of prolonged fasting, autophagic activity plateaus as the pool of readily degradable damaged proteins, dysfunctional organelles, and other cellular debris becomes substantially reduced. Concurrently, the organism transitions into a more energy-conserving metabolic state characterized by enhanced reliance on ketone bodies for cerebral and systemic energy demands, a marked attenuation of proteolysis to preserve lean body mass, and overall optimization of metabolic efficiency.

Autophagy is an energetically costly process involving the formation, trafficking, and lysosomal degradation of autophagosomes, and thus its sustained activation imposes significant bioenergetic demands. As substrate availability declines due to prior clearance, autophagic flux naturally diminishes. Additionally, hormonal adaptations during prolonged fasting–namely, increased secretion of growth hormone, suppressed insulin levels, and alterations in hypothalamic-pituitary-adrenal axis hormones such as cortisol–collectively act to inhibit excessive muscle protein catabolism and modulate autophagic pathways.

Prolonged elevation of autophagy carries the theoretical risk of autophagic cell death or detrimental degradation of essential cellular components. Therefore, regulatory feedback mechanisms likely downregulate autophagy after the initial robust activation phase to maintain cellular homeostasis. This modulation ensures autophagy continues at basal or moderate levels sufficient for quality control and turnover but prevents excessive self-digestion.

Hence, the dynamic regulation of autophagy during extended fasting reflects a complex integration of nutrient sensing, hormonal signaling, and energy balance, fine-tuning the balance between cellular repair and preservation to optimize organismal survival.

Deep Dive

The primary metabolic signal regulating autophagy during prolonged fasting and reductions in insulin is the mechanistic target of rapamycin, or mTOR. mTOR functions as a central cellular nutrient sensor that integrates signals related to energy status, growth factors like insulin, and nutrient availability.

When insulin and other growth-promoting signals are abundant–such as after eating–mTOR activity is high, which suppresses autophagy to prioritize growth and energy storage. During fasting, insulin levels drop, and energy stress increases, leading to a reduction in mTOR activity. This decrease acts as a green light for autophagy, allowing cells to initiate the breakdown and recycling of damaged proteins, organelles, and other cellular components.

This process helps maintain cellular health and supports metabolic adaptation during nutrient scarcity. While mTOR is a key regulator, autophagy is also influenced by other pathways, including AMP-activated protein kinase (AMPK), which senses cellular energy levels, and various upstream signals that together fine-tune the balance between growth and repair.

This metabolic pathway is the same signal that is used in strength training to prevent autophagic processes from targeting muscle mass. During resistance exercise, the activation of mTOR plays a crucial role in promoting muscle protein synthesis and growth. When you engage in strength training, mechanical stress and nutrient availability stimulate mTOR signaling, which shifts the cellular focus toward building and repairing muscle tissue rather than breaking it down.

By activating mTOR, strength training effectively suppresses autophagy in muscle cells, preventing excessive degradation of muscle proteins. This balance ensures that muscle mass is preserved or increased, even under conditions where the body might otherwise initiate autophagy to recycle cellular components.

In this way, mTOR serves as a key molecular switch that integrates environmental cues–such as nutrient intake and physical activity–to regulate whether cells prioritize growth and maintenance or engage in catabolic processes like autophagy. This delicate regulation allows the body to adapt efficiently to different metabolic states, whether during fasting or exercise.

This example of how autophagy can be both activated and suppressed depending on tissue type and physical activity is just one of many nuanced complexities often overlooked–or even flat out ignored–in mainstream conversations. Autophagy is not a simple on-or-off process that affects all cells uniformly; rather, it is tightly regulated in a context-dependent manner to meet the specific needs of different tissues and metabolic states.

For instance, while fasting may promote autophagy in the liver or brain to clear damaged components and support cellular renewal, the same fasting state combined with resistance training may simultaneously suppress autophagy in muscle tissue to preserve or build muscle mass. Additionally, factors such as nutrient availability, hormonal signals, exercise type, and intensity further modulate autophagy’s activity across the body.

Understanding these intricacies is crucial, especially when applying knowledge of autophagy to health, aging, or fitness. Simplistic narratives often fail to capture this dynamic regulation, which can lead to misunderstandings about the benefits or potential drawbacks of fasting, exercise, or other interventions targeting autophagy.

References

Shabkhizan R, Haiaty S, Moslehian MS, et al. The Beneficial and Adverse Effects of Autophagic Response to Caloric Restriction and Fasting. Adv Nutr. 2023;14(5):1211-1225. doi:10.1016/j.advnut.2023.07.006

Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181-192. doi:10.1016/j.cmet.2013.12.008

Exercise is often discussed as though it were a single activity with a single purpose. It is not. Different forms of training impose different kinds of stress, and the body adapts according to the structure of that stress rather than the brand name of the workout or the machine being used. Load, repetition range, session duration, rest intervals, movement speed, weekly frequency, and total volume all change the kind of result that training is likely to produce. That is why “adding exercise” is too vague to mean much on its own. The more useful question is what modality is being used and what adaptation that modality is actually built to drive.

Cardiovascular training is the broad category built around rhythmic work that primarily challenges the heart, lungs, and energy-producing systems through repeated movement. Running, cycling, rowing, swimming, incline walking, and similar work all fit here. In practical terms, cardio is often used to raise total energy turnover, improve conditioning, and increase tolerance for sustained work. That makes it useful, but it does not make it a complete body-composition tool by itself. Cardio can add expenditure and improve fitness, yet its mechanical stimulus for preserving muscle is limited compared with resistance training, and when volume rises too high during caloric restriction the added recovery demand can start working against lean-mass retention rather than supporting it. Cardio is therefore best understood as a useful contributor to expenditure and conditioning, not as the default answer to every fat-loss problem.

Endurance training should be treated as a distinct modality rather than as a synonym for all cardio. The difference is not simply that it lasts longer. Endurance work is built around sustaining output long enough that duration, pacing, and fatigue resistance become central to the adaptation. Physiologically, that gives it a different profile. Endurance exercise is commonly a blend of aerobic and anaerobic demand rather than a purely aerobic event. Earlier in the session and at higher efforts, glycolytic contribution can still be substantial because ATP has to be generated quickly enough to support the work being performed. But when moderate-intensity work is sustained long enough—often into the 30- to 60-minute range and beyond—the balance can shift more meaningfully away from early glycolytic dominance and toward greater reliance on oxidative metabolism, with lipolysis and fatty-acid contribution rising more strongly as the session continues. That does not make endurance work a loophole around energy balance, and it does not mean glycolysis disappears. It means the fuel mix, fatigue pattern, and recovery burden differ from shorter, harder, more glycolytically dominant cardio efforts. In practical terms, sustained moderate endurance work can often increase fat mobilization and energy turnover with less acute catabolic stress than repeatedly pushing higher-intensity, lower-duration conditioning.

That distinction matters because many people collapse all “cardio” into one bucket and then judge it mainly by how hard it feels. Harder is not always better. A shorter, more intense session may feel more productive because glycolytic demand is high and fatigue arrives quickly, but that is not the same thing as saying it is always the better fit for body-composition work, especially in a deficit. Moderate endurance work is often less dramatic, but it can be easier to recover from, easier to sustain, and better suited to increasing total work over time without repeatedly driving fatigue and tissue strain above what the phase can tolerate. In that sense, endurance work is not just “more cardio.” It is cardio with a different duration bias, a different substrate profile, and a different recovery profile.

Strength training has a different job entirely. Its primary emphasis is maximal force production rather than prolonged energy expenditure. Heavy loads, lower repetition ranges, and longer rest periods shift the adaptation toward force output, motor-unit recruitment, and neuromuscular efficiency. In a weight-loss context, that matters because strength-oriented resistance training provides one of the clearest signals that muscle tissue is still required. When intake is reduced, the body is already under greater pressure to conserve resources. A strong mechanical stimulus helps defend lean mass against that pressure. This is one reason strength-oriented training often fits dieting phases well: it preserves the signal for muscle retention without demanding the same total recovery burden as more voluminous training styles. Its value is not that it burns the most calories during the session. Its value is that it helps determine what kind of tissue is being protected while the diet is doing the main fat-loss work.

Hypertrophy training is related to strength training but not identical to it. Its emphasis is not peak force alone, but muscle growth through a larger total growth stimulus. Moderate loads, moderate repetition ranges, multiple hard sets, shorter rest periods, and greater overall training volume are commonly used because hypertrophy responds strongly to accumulated productive work. This modality can be highly effective when protein intake, energy availability, and recovery are all adequate. The problem is that those conditions become less reliable in a serious deficit. High-volume hypertrophy work increases tissue stress, repair demand, and recovery cost. When recovery capacity is already narrowed by low intake, trying to run aggressive hypertrophy volume can push the balance in the wrong direction. That does not make hypertrophy training useless during fat loss. It means the more aggressively the diet is pressed, the more carefully hypertrophy volume has to be managed so that it supports muscle retention rather than becoming a larger source of breakdown than the phase can recover from.

Hybrid and combined training methods sit between these categories because many real programs are not built around one pure adaptation. Some combine aerobic and resistance work across the week. Others blend strength, conditioning, and muscular work inside the same broader plan. In body-composition terms, that mixed approach often makes sense because fat loss, lean-mass retention, conditioning, and general fitness do not all come from one stimulus equally well. The tradeoff is that hybrid work has to be designed with some discipline. Combining everything indiscriminately is not the same thing as combining it intelligently. Even so, the clinical pattern is useful here. In one eight-month trial, resistance training alone increased lean mass by about 1.1 kilograms while aerobic training did not, and combining the two produced the best overall recomposition profile. That is the practical value of modality distinction. The point is not that one category must always exclude the others. The point is that different categories contribute different pieces of the result.

Once these distinctions are clear, a common mistake becomes easier to see. People often talk about “adding exercise” as though any movement added to the week should produce roughly the same class of outcome. That is too crude. A long walk, a heavy barbell session, a high-volume bodybuilding workout, a sustained endurance session, and a mixed conditioning circuit are not interchangeable just because they all raise heart rate or increase fatigue. They stress different systems, demand different recovery resources, and bias the body toward different adaptations. That is why exercise cannot be judged only by how tiring it feels or by what a machine estimates it burned. The more relevant question is what adaptation the modality is driving and whether that adaptation matches the body-composition goal and the recovery context in which the person is operating.

This becomes even more important during weight-loss phases. When energy is limited, exercise selection should not be guided only by which modality seems to create the most immediate exhaustion. It should be guided by what the phase is trying to protect and what the body can realistically recover from. Modalities that support lean-mass retention and manageable recovery often deserve more emphasis than modalities that simply add fatigue. In higher-energy phases or more performance-oriented contexts, that balance can shift because the body has more resources available to support growth, volume, and prolonged work. The modality itself has not changed. The context in which it is being used has changed. That is why exercise selection is inseparable from the broader regimen rather than standing outside it as a separate issue.

Seen clearly, exercise modalities are not just categories for organizing a gym schedule. They are different ways of applying stress to produce different physiological outcomes. Cardio and endurance work are strongest when conditioning, work capacity, additional energy turnover, and sustained output are needed, though endurance deserves separate consideration because its longer moderate structure changes substrate contribution and recovery cost in ways shorter, harder cardio does not. Strength work is strongest when force production and lean-mass defense are the priority. Hypertrophy work is strongest when the goal is muscle gain and the body has enough energy and recovery capacity to support it. Hybrid approaches are strongest when more than one adaptation has to be pursued at the same time without pretending they are all the same thing. Once those distinctions are in place, the next question is how exercise changes fuel use and fat mobilization while the work is actually being performed.

It is true there are gaps and limitations; however, there's ample conclusive evidence on all major issues besides the "loose" fields like gut microbiome or emerging sciences like epigenetics. Weight loss settled. Insulin resistance reversal settled. Long-term maintenance settled. Diet "superiority" settled.

Don't think so? I challenge you.

For anyone interested in any clinical studies on the gamut of health and nutrition to into the depths of physiology or outcomes, please ask. I have literally read thousands and I literally have curated lists of hundreds available full text.

Severe caloric deprivation does not mean starvation, and that distinction matters because the terms are often used as if they are interchangeable when they are not. People routinely collapse very different conditions into the same category: aggressive restriction, rapid fat loss, nutrient deficiency, emaciation, and medical starvation are treated as though they are all just different ways of describing the same thing. They are not. If that confusion is left uncorrected, the entire discussion becomes sloppy, because the warning attached to one state gets wrongly applied to all the others.

Starvation is not simply the act of eating very little for a period of time. It is a physiological state in which available energy becomes insufficient to meet the body’s needs and biological compromise begins to deepen rather than stabilize. That is a very different claim from saying someone is under severe caloric restriction. The method and the state are not the same thing. Severe caloric deprivation can exist without starvation, and under the wrong conditions it can contribute to or worsen starvation. That is exactly why the wording here matters.

People with adequate body-fat reserves are not automatically in starvation simply because intake is very low or even zero for a period of time. That point is basic, but it is constantly lost in public discussion. The body is built to store energy and then use it when incoming energy is reduced or absent. That is not a system failure. That is one of the system’s intended functions. When meaningful body-fat reserves are present, the body is not immediately forced into a state of catastrophic tissue loss just because food intake drops hard.

This is also where emaciation has to be distinguished from simple weight loss or even aggressive fat loss. Emaciation is not just “very lean” and it is not just “losing weight quickly.” It reflects a state of severe depletion in which energy reserves have been driven down toward an essential threshold and the body no longer has meaningful room to absorb continued loss safely. Essential body fat is not optional storage. It is the minimum fat required for normal physiological function. Once a person is pushed toward that floor, the context changes. The issue is no longer simply that intake is low. The issue is that the reserve buffer that made aggressive restriction tolerable is no longer meaningfully there.

That is why severe caloric deprivation does not mean starvation by default, but it can move in that direction under the wrong conditions. A person with substantial fat reserves is in a very different physiological position from a person who is already depleted, undernourished, or approaching emaciation. The body is built to transition toward stored-energy use under restriction, and that is normal physiology, not evidence of collapse. But that does not continue indefinitely without consequence. The distinction is not whether calories are low. The distinction is whether the person still has the reserves and physiological stability to tolerate that restriction without being pushed into a genuinely compromised state.

People with adequate body-fat reserves are not automatically in starvation simply because intake is very low or even zero for a period of time. Starvation has both an energy component and a nutrient component. That matters because people often reduce the issue to calories alone and ignore the fact that the body is built with reserve systems for both. Body fat functions as stored energy, and the body can draw on it when intake drops. Nutrients are different, but they are not starting from zero every morning either. The body also carries meaningful nutrient reserves, which is why low intake does not automatically produce immediate deficiency the moment food intake falls hard.

Body fat has to be understood first because it is the clearest part of the distinction. Essential body fat is approximately 3% for men and 12% for women. Those are not cosmetic numbers. They reflect the minimum fat required to support normal physiological function. Emaciation is not just rapid weight loss, and it is not simply becoming leaner than average. It is a state of severe depletion in which reserves are driven down toward that essential floor and the body no longer has meaningful room to absorb continued loss safely. That is a very different situation from an overweight or obese person drawing heavily on stored fat during a structured phase of severe caloric deprivation.

That is why low intake by itself does not define starvation. A person with substantial body-fat reserves is in a very different physiological position from someone who is already depleted, undernourished, or approaching emaciation. The body is designed to shift toward stored-energy use under restriction, and that is normal physiology, not evidence of collapse. But that does not continue indefinitely without consequence. Once energy reserves are pushed low enough, and especially once nutrient status is also compromised, the picture changes. That is exactly why severe caloric deprivation does not mean starvation, but can move in that direction under the wrong conditions.

Low intake does not automatically mean immediate nutrient deficiency. The body does not start from zero the moment calories fall hard. It carries stored vitamins, minerals, and other nutritional reserves, which is why deficiency symptoms do not appear overnight. That matters because starvation language is often used as if the moment intake drops, the body is instantly sliding into the same condition seen in severe nutritional deprivation. That is not how human physiology works.

That is why the few nutritional-deprivation studies that do exist are so important, and also why many people are not familiar with them. They are commonly not conducted because they are considered unethical. One of the best-known examples is the Sheffield Experiment on the Vitamin C Requirement of Human Adults, conducted on World War II conscientious objectors and later discussed by Krebs. It was conducted in a period when ethical protections were far weaker, especially for stigmatized or politically vulnerable groups such as conscientious deserters. That history matters because it helps explain both why the evidence base is limited and why the available work carries so much weight when trying to understand how long deficiency can actually take to emerge.

Nutritional storage is why deficiency diseases like scurvy are not something that appears in a day or two. Scurvy is caused by vitamin C deficiency, and even there symptoms can take months to emerge, with about six months commonly cited. That is a critical point because vitamin C is not one of the nutrients the body stores especially well compared with others. If even vitamin C deficiency can take that long to fully develop, then the idea that severe caloric deprivation automatically becomes nutritionally dangerous the moment food intake drops is plainly wrong.

Recovery is part of this discussion for the same reason nutrient status is. Severe caloric deprivation does not automatically mean starvation, but it does increase the importance of recovery. When intake is low, the body is already operating under greater stress, which means bad recovery decisions can push the situation in the wrong direction much faster. That does not make restriction itself the problem. It means the recovery margin is smaller, and that margin can be eaten up quickly by poor judgment.

Overtraining is usually discussed as an exercise problem, but the underlying issue is recovery. Physical training is not the only stressor. The real problem is that the body is not recovering well enough to keep up with the stress being imposed on it. That is why this belongs here. Poor recovery is not just about training volume. It also includes inadequate nutritional support, inadequate reserves, inadequate sleep, and an overall physiological state that is already under more strain than normal. That is also why overtraining is often more accurately understood as under-recovery.

Severe caloric deprivation carried on long enough without a proper break can contribute to that problem on its own. As calorie and nutrient depletion accumulate, the room the body has to recover well becomes smaller. Poor sleep can worsen that further. So can persistent fatigue, poor refeeding, ongoing deficiency, repeated hard phases without enough recovery between them, and the general strain of trying to push output while inputs remain low. In that setting, the issue is not just that a person is “dieting hard.” The issue is that recovery capacity is being outpaced, and once that starts happening, fatigue, impaired repair, reduced training tolerance, and broader physiological strain become much more likely.

That is where aggression on top of aggression becomes a safety issue. Severe caloric deprivation is already an aggressive intervention. Layering aggressive training on top of it can make a bad situation worse quickly. When recovery is already under more pressure, intense or excessive training can accelerate under-recovery and push a person toward rapid overtraining.

That is why exercise and overtraining belong in a safety discussion. Exercise can still be beneficial, but only when it matches recovery capacity rather than being piled on blindly. Low-intensity, low-volume strength work and light activity can fit this context well, and that will be discussed later in the Diet Versus Exercise chapter. For now, the important point is simple: know your limits, understand what kind of exercise is helpful here, and recognize that both activity level and training type are part of safety.

Taken together, that is the distinction this section is trying to protect. Severe caloric deprivation does not mean starvation, immediate nutrient collapse, or automatic overtraining. Those outcomes are not built into the method by default. They become more likely when the wrong person uses it, when it is carried too far, when nutritional status and recovery are poor, or when additional stress is layered on carelessly. That is why precision matters here. The danger is not in confusing a strong method with a weak one. The danger is in confusing a controlled physiological process with a genuinely compromised state.

Big things depend on small things. That is not a slogan. It is how progress works.

People notice the dramatic parts of change. They notice the breakthrough, the comeback, the hard day, and the major transformation. But those larger moments are built from smaller actions repeated long enough to become reliable. The big thing is not separate from the small thing. The big thing is the small thing repeated and carried forward over time. If someone is still failing at the small things, the big things are not waiting nearby. They are still out of reach.

Show me someone who cannot be trusted with the small things, and I will show you someone who cannot be trusted with the big things. Not because the big things are separate, but because they depend on the small things being handled first. If a person cannot handle the smaller requirement, there is no good reason to assume they will suddenly handle the larger one under more pressure.

If you cannot bench 225 pounds, you are not about to bench 500 because the moment feels important. The lighter weight is not a side issue. It is the path. It is the requirement. The same logic applies here. If you cannot repeat the smaller behaviors that support change, you should not expect to carry the larger burden when life becomes difficult.

This is why repetition matters. Repetition makes behavior more consistent, but it also makes behavior easier. It lowers friction. It makes the action more familiar and less dependent on mood, effort, or perfect conditions.

That matters when life gets harder. If the right action still feels awkward, foreign, and mentally expensive, you are less likely to do it when you are tired, stressed, hungry, discouraged, distracted, or tempted. But if you have repeated that action enough, it has a better chance of holding when you need it.

A lot of people treat useful practices as tools to use only when they are already struggling. That is backwards. A practice used only when needed is usually weak. It has not been repeated enough to become easier. It has not been strengthened enough to carry weight.

People think they can save better behavior for the hard days. They act as if the hard day is the time to start building it. It is not. Hard days test whether the easier days built it well enough.

That is the role of the mundane. The mundane is not filler. It is training. It is the repeated handling of smaller requirements until they become manageable, then easier, then more automatic, and then strong enough to support something larger.

The purpose is not to perform discipline. The purpose is to lower the cost of doing the right thing. You take on what you can handle. You repeat it until it gets easier. Then you build again. That is how people get stronger in almost every area that matters. They do not jump to the highest demand and hope intensity carries them. They build capacity by practicing at a level they can repeat, then making that level normal.

This is also why many people stay stuck while insisting they are trying. They want bigger outcomes while they remain unreliable with smaller practices. They want the result without mastering the requirement that leads to it. They keep looking upward while the foundation underneath them is still weak.

That is not ambition. It is disorder. If the basics are not stable, the basics are still the problem. Advanced methods do not solve that. They usually just give the person a more complicated way to avoid it.

The mundane things matter because they are the things you can repeat. A structured breakfast. A logged meal. A grocery rule. A consistent bedtime. A fallback meal instead of an impulsive one. A routine that removes one more decision.

None of those look impressive on its own. None of them feels like a major breakthrough. That is exactly why people dismiss them, and exactly why they matter. They are small enough to practice often. What can be practiced often can be strengthened. What is strengthened becomes easier to execute. What becomes easier to execute is more likely to hold when life gets ugly.

This is where people often get the process backwards. They focus on the larger struggle while neglecting the smaller requirements that make the larger struggle possible. They want to resist temptation, but they refuse to remove tempting food from easy access. They want to stop overeating, but they will not log their food. They want better appetite control, better energy, and better fat loss, but they will not address insulin resistance, poor sleep, or a chaotic food environment. They want consistency, but they will not repeat the smaller practices long enough for consistency to become easier.

Then they act as if the problem is mysterious. Usually it is not. Usually the bigger failure is being built from smaller failures that were left in place.

This is not about chasing dramatic tactics. It is about handling the smaller requirements that larger success depends on. If those smaller requirements are still being neglected, the bigger goal is still being asked to stand on a weak foundation.

Meaning

"I'm healing, not hungry" is a powerful mantra while dieting because it reframes the experience from one of deprivation to one of restoration. Hunger during a fast can be uncomfortable, but this phrase reminds you that the sensation isn’t a signal of harm–it’s a signal of change. Your body is shifting into repair mode: recycling damaged cells, reducing inflammation, and burning through excess fat and stored glucose. By saying “I’m healing, not hungry,” you reinforce the idea that the discomfort you feel isn’t pointless–it’s purposeful. It helps shift your mindset away from scarcity and toward empowerment, reminding you that dieting is not about starving yourself, but about giving your body the space and time it needs to reset, repair, and thrive.

Anecdotal

Because of my experience with prolonged fasting for over 20 years, I’ve mastered hunger. That doesn’t mean this mantra no longer matters or that it’s any less valuable–it simply means I swap out “hunger” for whatever challenge I’m currently facing. The structure stays the same, but the target shifts. That’s the beauty of a good mental tool: it adapts with you, and it keeps serving you long after the original struggle has changed.

This is actually a perfect example of how these tools are never meant to be rigid or one-size-fits-all. They can absolutely be “end all” in the sense that they work, they’re reliable, and you can take them anywhere in life–but they become far more powerful when you personalize them. Tailoring a mantra to your real circumstances makes it resonate deeper, stick longer, and hit exactly where your motivation needs support. When you make these tools your own, they stop being something you practice and start becoming a part of who you are.

Gluconeogenesis is the metabolic process by which the body produces glucose from non-carbohydrate sources, primarily in the liver and to a lesser extent in the kidneys. It is not a fringe backup pathway that appears only under extreme conditions. It is a normal part of human energy metabolism and becomes more prominent whenever dietary carbohydrate is too low to cover ongoing glucose demand. That is one of the main reasons the body can continue functioning when carbohydrate intake falls without immediately collapsing into hypoglycemia or complete glycogen exhaustion.

That matters because glucose demand does not disappear when carbohydrate intake is reduced. Some tissues and cell types still require glucose, and others continue to function more effectively when some glucose remains available even if fat and ketones are contributing more heavily elsewhere. Low-carbohydrate or ketogenic dieting therefore does not eliminate carbohydrate physiology from the system. It changes the route by which glucose is being supplied. Instead of relying primarily on incoming dietary carbohydrate, the body relies more heavily on internally produced glucose. That is the central context in which gluconeogenesis belongs. It is not a side note to ketosis. It is one of the processes that determines how low-carbohydrate states are actually sustained.

The main substrates are well established. Lactate can be recycled back into glucose. Glycerol released from triglyceride breakdown can be converted into glucose. Glucogenic amino acids can also enter the pathway and support glucose production. This is why protein remains metabolically important during carbohydrate restriction in a way that is often poorly understood. Protein is not only supporting tissue turnover and repair. It can also contribute substrate for endogenous glucose production. That does not mean the body is indiscriminately converting protein into sugar. It means protein remains part of the fuel economy, and under low-carbohydrate conditions some of its carbon skeletons can be directed toward maintaining blood glucose and supporting glycogen-related physiology when direct carbohydrate intake is limited.

Gluconeogenesis should also be understood as a regulated, demand-driven, throttled process rather than a chaotic one. The body does not simply flood the bloodstream with glucose because protein was eaten. Glucose is produced as needed, in the amount required to maintain function under the current conditions. That throttling matters. It is one reason higher-protein low-carbohydrate diets can remain metabolically stable while still producing enough endogenous glucose to alter glycogen status and reduce the drive for deeper ketone production. It is also why the insulin response in this setting is usually modest rather than dramatic. When glucose is being delivered gradually through a controlled endogenous pathway rather than arriving abruptly as a large carbohydrate load, the hormonal handling is different. The body is still managing glucose, but it is doing so through a slower route.

That point clarifies one of the most common misconceptions about low-carbohydrate and ketogenic dieting. Many people assume that once dietary carbohydrate is removed, glycogen physiology becomes largely irrelevant and glycogen-associated water weight is no longer part of the picture. That is false. Glycogen does not vanish from energy metabolism simply because direct carbohydrate intake falls. If the body can continue producing glucose internally, then glycogen can continue to matter internally as well. That does not mean glycogen stores remain identical to those seen on a higher-carbohydrate diet, but it does mean they are not metabolically absent. The system is constrained, not deleted.

This is why low-carbohydrate or keto-style dieting does not eliminate glycogen-associated water shifts from weight change. Earlier in the chapter, glycogen was already shown to be stored with approximately 3 to 4 grams of water for every gram of glycogen. That relationship does not stop being true in a low-carbohydrate state. If enough glucose is being generated endogenously to support at least partial glycogen restoration, then glycogen-associated water can still move with it. The practical consequence is that people can still see meaningful short-term scale fluctuations even when they are eating very little carbohydrate. Those fluctuations may be smaller, slower, or more constrained than on a higher-carbohydrate diet, but they are still part of the system. Low-carbohydrate dieting changes glycogen status and the route of glycogen support. It does not remove glycogen-water dynamics from body-weight interpretation.

That is also why glycogen replenishment on a low-carbohydrate diet is so often misunderstood. People see the early drop in body weight, correctly recognize that glycogen and water have been lost, and then incorrectly assume that glycogen cannot be restored without a deliberate carbohydrate refeed. But glycogen replenishment does not depend exclusively on dietary starch or sugar arriving at the intestine. It depends on glucose becoming available to the system. Under low-carbohydrate conditions, part of that glucose can still be supplied through gluconeogenesis. This is one reason protein-adequate low-carbohydrate dieting can still support meaningful glycogen restoration over time, particularly when total energy intake is sufficient and when exercise has created a strong local pull toward replenishment. The body is not limited to one entry route.

Once that is understood, the relationship between glycogen depletion and ketosis becomes much clearer. Ketosis is driven by the metabolic state created when glucose availability falls far enough and glycogen depletion advances far enough that the system is pushed more heavily toward fat-derived fuel and ketone production. In that state, macronutrient ratios become secondary as long as glycogen remains sufficiently constrained and caloric intake remains low enough to preserve the pressure toward ketogenesis. That is exactly why the fasting-mimicking diet work of Brandhorst et al. is so useful here. In both Brandhorst et al. 2015 and Brandhorst et al. 2024, the intervention was designed to reproduce fasting-like metabolic effects on glucose and ketone bodies even though carbohydrate still provided roughly 43% of calories on day 1 and about 47% on days 2 through 5. That is not what the popular macro-ratio version of ketosis would predict. It makes sense, however, once ketosis is understood as a consequence of glycogen depletion and energy restriction rather than as a simple function of carbohydrate percentage alone.

That same logic also explains why trace ketones on a high-protein low-carbohydrate diet are so often misread as “fat adaptation.” When gluconeogenesis is sufficient to keep providing glucose, the pressure for higher ketone production falls. The body is still in a carbohydrate-restricted environment, but it is no longer under the same degree of glycogen-driven pressure to deepen ketogenesis. In that setting, low ketones do not prove that some special long-term adaptation has made ketones unnecessary. They usually show that endogenous glucose production is still substantial enough to cover more of the remaining demand. The simpler explanation is the correct one: glycogen depletion drives ketosis, and when gluconeogenesis partially relieves that depletion pressure, ketone levels stay lower. That is ordinary fuel regulation, not a magical adaptation state.

This is where the phrase “fat adaptation” tends to create more confusion than clarity. The body does not need to discover a new enzyme system to explain why someone on a higher-protein low-carbohydrate diet may show only trace ketones. The relevant mechanisms are already sufficient: glycogen status changes, substrate availability changes, insulin exposure changes, endogenous glucose production continues, and ketone demand shifts accordingly. The person may still be relying more heavily on fat than before. They may still be metabolically improved. They may still be getting real benefit from the diet. But that does not require an exotic explanation. It requires ordinary fuel regulation being understood correctly.

This distinction also helps separate a truly deeper ketogenic state from the much broader category of high-protein low-carbohydrate dieting. Many diets called “keto” are metabolically better described as low-carbohydrate diets with substantial protein intake and substantial gluconeogenesis. They may still reduce insulin exposure, improve appetite control, and improve metabolic stability. They may still be highly effective. But they are not the same thing as a diet maintaining consistently higher ketone production under more carbohydrate- and protein-restricted conditions. In one case, ketone production is carrying more of the burden. In the other, endogenous glucose production is carrying more of it.

Gluconeogenesis also helps explain why low-carbohydrate dieting does not remove the need to think carefully about protein. Protein is doing more than one job in this setting. It supports tissue maintenance and repair, but it can also be called upon to support glucose production. That does not mean muscular catabolism automatically spirals out of control as soon as carbohydrate falls. The process is throttled, not lawless. Glucose production rises according to demand, and the body is not infinitely eager to dismantle muscle tissue when other substrates and adequate dietary protein are available. But the pressure does become more relevant when glycogen remains constrained, glucose demand persists, and protein intake or overall energy availability is not sufficiently protective. Under those conditions, protein is being asked to serve both anabolic and glucose-supporting roles at the same time, and that tension matters more.

This is one reason prolonged fasting, severe caloric restriction, and protein-adequate low-carbohydrate dieting are not metabolically identical situations. Gluconeogenesis is present across all of them, but the context surrounding it is different. In a protein-adequate low-carbohydrate diet, endogenous glucose production can be supported while lean tissue is better protected. In more extreme states, where glycogen has been constrained longer, intake is lower, and protein is less available, the pressure on lean tissue rises because the need for endogenous glucose has not disappeared even while external support has. The key point is not that gluconeogenesis is dangerous. The key point is that it is central enough to make protein adequacy and dietary context matter more than many people realize.

There is also a small but useful connection here to the thermic effect of food. Low-carbohydrate dieting does not bypass the metabolic cost of fuel handling. It changes the route by which fuel is processed. Protein still has to be digested, absorbed, and metabolized. Glucose still has to be produced internally when dietary carbohydrate is low. That conversion work is part of the system’s ordinary energetic cost. This is not a separate miracle advantage layered on top of everything else. It is one more reminder that energy metabolism is mediated through real biological processing steps, not just through raw calorie labels.

Seen clearly, gluconeogenesis does not remove carbohydrate physiology from low-carbohydrate dieting. It preserves part of it indirectly. That is why glycogen can still matter when carbohydrates are low, why glycogen-associated water can still shift on the scale, why ketosis is driven by the metabolic consequences of glycogen depletion rather than by simplistic macro-ratio rules, and why trace ketones do not prove some special adaptation state. Low-carbohydrate dieting changes the fuel environment, but it does not erase the body’s need to manage glucose. Gluconeogenesis is one of the main ways that management continues when dietary carbohydrate is scarce. Once that is understood, the broader questions about ketosis, so-called fat adaptation, and the real distinction between low-carbohydrate and truly ketogenic states become much easier to interpret correctly.

​

TL;DR;

Muscle breakdown is different from general catabolism and is tightly regulated. Prolonged fasting triggers protective mechanisms like increased growth hormone to preserve muscle. If you’re fasting for less than seven days, muscle loss is negligible and easily prevented–and even beyond that, it’s far less severe than most people think.

Fundamentals

The concept of muscular catabolism is often mistakenly equated with general metabolic catabolism, but these processes are distinct. Catabolism–the breakdown of molecules to release energy–is a continuous process that occurs regardless of fasting or feeding state. However, catabolic pathways specifically targeting muscle protein degradation differ significantly from overall metabolic catabolism. In many physiological conditions, mechanisms exist that preserve muscle mass by preferentially utilizing other energy substrates, thereby sparing muscle protein from breakdown. This muscle-sparing effect can persist even during states characterized by high metabolic catabolism, such as prolonged fasting or illness, through hormonal regulation and substrate utilization adaptations.

Prolonged fasting triggers a range of powerful physiological responses that help protect the body from excessive muscle breakdown. One key adaptation is the marked increase in growth hormone (GH) secretion, which supports the preservation of lean muscle mass by promoting protein synthesis and limiting protein degradation. Alongside this, fasting induces hormonal shifts–such as elevated catecholamines and glucagon–that encourage the body to rely more heavily on fat stores for energy, thereby sparing muscle tissue. Despite reductions in insulin levels during fasting, these complex hormonal changes collectively create a metabolic environment that minimizes muscle loss even in the face of sustained calorie deprivation.

Fasting improves insulin sensitivity and shifts the body into a state of nutritional ketosis, where it burns fat (and ketones) as its primary energy source. Ketones, particularly beta-hydroxybutyrate, have been shown to have muscle-sparing properties. They help reduce the need for the body to convert amino acids into glucose through gluconeogenesis, thereby preserving muscle protein.

Fasting also activates autophagy, a vital cellular repair process that removes damaged or dysfunctional components within muscle cells. By clearing out these cellular debris, autophagy helps maintain muscle cell integrity and promotes overall cellular health. This enhanced cellular cleanup not only supports muscle efficiency but may also improve recovery and resilience, contributing to better muscle function during and after periods of stress or energy restriction.

Fasting can also help prevent catabolism by positively influencing protein turnover. Initially, protein breakdown increases to supply amino acids for glucose production, but with prolonged fasting, the balance shifts toward reduced protein degradation and greater preservation of lean muscle mass. Overall, protein turnover decreases, sparing muscle protein and helping maintain essential bodily functions until feeding resumes.

Moreover, when fasting is paired with adequate protein intake during eating windows and strength training, the body receives the necessary signals and building blocks to maintain or even build muscle during refeeding. This means that building muscle is possible if refeeding is adequate and long enough to support hypertrophy.

Muscular catabolism only becomes necessary primarily during severe glucose depletion because, despite the brain’s ability to adapt by using ketones as an alternative fuel, the body still requires a minimal amount of glucose to support critical functions. This minimal glucose demand is essential since certain tissues and cellular processes depend on glucose and cannot be fully substituted by ketones.

It is important not to confuse this with severe hypoglycemia. Individuals with healthy insulin function and high insulin sensitivity can maintain low blood glucose levels without experiencing hypoglycemic symptoms. However, the brain cannot directly utilize fatty acids for energy due to the protective nature of the blood-brain barrier (BBB), which limits fatty acid passage. This limitation partly drives the body’s metabolic shift toward increased ketone production during prolonged fasting or carbohydrate restriction. As ketone levels rise, they provide an efficient alternative energy source for the brain, reducing its glucose requirements and thereby helping to preserve muscle tissue from excessive catabolism.

In summary, while excessive or prolonged fasting without nutritional support can become catabolic, properly implemented fasting–especially intermittent fasting–can encourage the body to conserve muscle tissue, rely more on fat for energy, and optimize hormones that promote a muscle-preserving, anti-catabolic state.

Deep Dive

GH stimulates the production of insulin-like growth factor 1 (IGF-1), which promotes muscle cell growth and protein synthesis by activating signaling pathways such as PI3K/Akt/mTOR. This process supports muscle repair and growth while counteracting protein breakdown. Additionally, GH and IGF-1 reduce the activity of proteolytic systems like the ubiquitin-proteasome and autophagy-lysosome pathways, limiting muscle protein degradation during catabolic states. GH also enhances lipolysis, increasing the mobilization of free fatty acids from adipose tissue to serve as alternative energy sources. This shift toward fat oxidation spares muscle protein from being used for energy. Furthermore, GH promotes nitrogen retention in muscle, indicating a positive protein balance necessary for muscle maintenance. While GH’s effects on insulin sensitivity are complex, it helps coordinate anabolic and catabolic signals, particularly during fasting or stress, thereby supporting muscle preservation.

Muscle catabolism contributes amino acids to gluconeogenesis, the process by which these amino acids are converted into glucose. This process is tightly regulated to maintain metabolic balance. Under normal dietary conditions, gluconeogenesis facilitates a gradual and controlled release of glucose derived primarily from dietary proteins, leading to a moderated insulin response and more stable blood glucose levels–effects commonly observed with low-carbohydrate diets. Even during periods of severe glucose depletion, gluconeogenesis remains carefully regulated rather than accelerating unchecked. This regulation helps prevent excessive muscle protein breakdown by avoiding unnecessary overcompensation for low glucose availability.

The anti-catabolic effects of strength training arise from several key physiological mechanisms, with the activation of mTOR (mammalian target of rapamycin) playing a central role. Mechanical tension generated during resistance exercise stimulates mTOR, a critical regulator of muscle protein synthesis (MPS), thereby promoting muscle maintenance and inhibiting proteolysis.

Importantly, mTOR is intricately linked to the signaling pathways that regulate autophagy–an intracellular degradation process activated by mTOR inhibition. This balance between anabolism and catabolism is essential for cellular homeostasis. Strength training, by activating mTOR, suppresses autophagy in muscle tissue, which is beneficial as autophagy primarily targets unused or damaged cellular components. Therefore, mTOR activation through resistance exercise protects muscle tissue from unnecessary breakdown, supporting muscle preservation and growth.

It is important to recognize that anabolic and catabolic processes, including autophagy, operate in a tightly regulated balance rather than indiscriminately targeting all tissues. These processes are highly selective and context-dependent, ensuring that muscle and other vital tissues are preserved or repaired as needed. Autophagy, for example, primarily targets damaged or dysfunctional cellular components to maintain cellular health and efficiency, rather than causing wholesale degradation of healthy muscle tissue. Likewise, anabolic signaling pathways like mTOR selectively promote protein synthesis in response to mechanical and nutritional cues. This dynamic interplay allows the body to adapt optimally to varying physiological states–whether during fasting, exercise, or recovery–by preserving essential tissues while efficiently removing or recycling components that compromise cellular function.